Risk Factors for Recurrence in Completely Resected pT1/2N1 Non-small Cell Lung Cancer |
Park Inkyu
(Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine)
Chung Kyung Young (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) Kim Kil Dong (Department of Thoracic and Cardiovascular Surgery, Eulji University School of Medicine) Joo Hyun Chul (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) Kim Dae Joon (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) |
1 | Osaki T, Nagashima A, Yoshimatsu T, Tashima Y, Yasumoto K. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 2004;43:151-7 DOI ScienceOn |
2 | Scott WJ, Howington J, Movsaa B. Treatment of stage II non-small cell lung cancer. Chest 2003;123:188S-201S DOI ScienceOn |
3 | Naruke T, Suemasu K, Ishogawa S. Lymph node mapping and curability at various level of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832-9 |
4 | Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma. Based on the 1997 TNM-staging Classificaiton: The Japanese experience. Ann Thorac Surg 2001;71:1759-64 DOI ScienceOn |
5 | Rea F, Marulli G, Callegaro D, et al. Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2? Lung Cancer 2004;45:215-20 DOI ScienceOn |
6 | Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7 DOI PUBMED ScienceOn |
7 | Strauss M, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol (Meeting Abstracts) 2004;22:7019 DOI |
8 | Sayar A, Turna A, Solak O, Urer N, Gurses A. Prognostic significance of surgical-pathologic multistation N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg 2004;25:434-8 DOI ScienceOn |
9 | Arriagata R, Bergan B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60 DOI ScienceOn |
10 | van Velzen E, Snijder RJ, de la Riviere AB, Elbers HRJ, van den Bosch JMM. Lymph node type as a prognostic factor for survival in T2N1M0 non-small cell lung carcinoma. Ann Thorac Surg 1997;63:1436-40 DOI ScienceOn |
11 | Sawyer TE, Bonner JA, Gould PM, et al. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1171-6 DOI ScienceOn |
12 | Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p) T1-2N1M0 non-small cell lung cancer. Eur J Cardio Thorac Surg 2001;19:555-561 DOI ScienceOn |
13 | Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World health organization international histologic classification of tumours. 3rd ed. Springer-Verlag. 1999 |
14 | Riquet M, Manac'h D, Le Pimpec-Barthes F, Dujon A, Chehab A. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg 1999;67:1572-6 DOI ScienceOn |
15 | Keller S, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with Stage II and IIIa non-small cell lung cancer. Ann Thorac Surg 2000;70:358-66 DOI PUBMED ScienceOn |
16 | Marra A, Hillejan L, Zaboura G, Fujimoto T, Greschuchna A, Stamatis G. Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2003;125:543-53 DOI ScienceOn |
17 | Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer. Intergroup JBR.10. J Clin Oncol (Meeting Abstracts) 2004;22:7018 DOI |
18 | Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Kaysuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. An analysis in each pathologic stage. J Thorac Cadiovasc Surg 1995;110:601-5 DOI ScienceOn |
19 | van Rens MTM, de la Riviere AB, Elbers HRJ, van den Bosch JMM. Prognostic assessment of 2361 patients who underwent pulmonary resection for non-small cell lung cancer, Stage I,II, and IIIA. Chest 2000;117:374-9 DOI ScienceOn |
20 | Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K. Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1994;107:1398-402 |